Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response

• Genomic Experimental Approaches in Oncology.- Toward the Realization of the Promise of Microarrays in Oncology.- Cell-Based Models to Identify Genetic Variants Contributing to Anticancer Drug Response.- Proteomic Analysis in Cancer Patients.- MicroRNAs and Discovery of New Targets.- Pharmacogenomics of the National Cancer Institute’s 60-Tumor Cell Panel.- Use of Single-Nucleotide Polymorphism Array for Tumor Aberrations in Gene Copy Numbers.- Pharmacogenomics of Toxicity and Response of Chemotherapy.- Concordance Between Tumor and Germline DNA.- Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer.- BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients.- Role of Thymidylate Synthase Gene Variations in Colorectal Cancer Patients.- Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants of the Thiopurine S-Methyltransferase Gene.- Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic Malignancies.- DNA Repair and Mitotic Checkpoint Genes as Potential Predictors of Chemotherapy Response in Non-Small-Cell Lung Cancer.- Dihydropyrimidine Dehydrogenase (Dpyd) Gene Polymorphism: Portrait of a Serial Killer.- Impact of UDP-Glucuronosyltransferase 1A Haplotypes on Irinotecan Treatment.- Microarray Profiling in Breast Cancer Patients.- Role of the Folate-Pathway and the Thymidylate Synthase Genes in Pediatric Acute Lymphoblastic Leukemia Treatment Response.- Pharmacogenomics in Clinical Drug Development in Oncology.- Pharmacogenomics in Drug Development: A Pharmaceutical Industry Perspective.- Identification of Pharmacogenomic Biomarker Classifiers in Cancer Drug Development.- Toxicogenomics Application to OncologyDrug Development.- Strategies to Identify Pharmacogenomic Biomarkers: Candidate Gene, Pathway-Based, and Genome-Wide Approaches.

From the reviews: "The chapters of this book, written by outstanding scientists in the field of cancer pharmacogenomics, clearly show how DNA information from both the host and the tumor should be taken into account for rational selection of drug therapies in cancer patients. ... the book provides a comprehensive and in-depth view of the field of cancer pharmacogenomics. The book is informative for clinicians, for people involved in development of cancer therapeutics on industrial level, and any scientists who are interested in cancer biology." (C. Altaner, Neoplasma, June, 2009) "The chapters of this book, written by outstanding scientists in the field of cancer pharmacogenomics ... . the book provides a comprehensive and in-depth view of the field of cancer pharmacogenomics. The book is informative for clinicians, for people involved in development of cancer therapeutics on industrial level, and any scientists who are interested in cancer biology." (C. Altaner, Neoplasma, April, 2009)